TED
09.09.19
FDA Grants Priority Review of Horizon Therapeutics’ Teprotumumab BLA for the Treatment of Active Thyroid Eye Disease (TED)Source: Horizon Therapeutics
08.19.19
American Journal of Ophthalmology Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)Source: Horizon Therapeutics
07.10.19
Horizon Therapeutics Submits Biologics License Application for the Treatment of Active Thyroid Eye DiseaseSource: Horizon Therapeutics
10.31.18
Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOSource: Horizon Pharma
09.04.18
Horizon Pharma Completes Enrollment of Phase 3 Trial of Teprotumumab for Treatment of Active Thyroid Eye DiseaseSource: Horizon Pharma